Summary Widely disseminated neuroblastoma in children older than infancy remains a very poor prognosis disease. Even the introduction of marrow ablative chemotherapy with autologous rescue has not significantly improved the outlook for these children, presumably because of a failure to eradicate minimal residual disease. One additional approach which may hold promise is the use of immunomodulation with cytokines such as IL2 in the setting of minimal residual disease (MDR), for example after intensive chemotherapy and ABMT. However, considerable variability in the susceptibility of neuroblastoma cells to natural killer (NK) and lymphokine-activated (LAK) killing has been observed, and it is presently unclear how NK and LAK cells recognise neuroblastoma cells. In this paper we examine expression of cell adhesion molecules on neuroblastoma to determine which of these modify interaction with NK and LAK cells. We find that LFA-3 (CD58), the ligand for CD2 is of predominant importance in predicting susceptibility of neuroblastoma to the cytotoxic actions of NK and LAK cells, while expression of ICAM-1 (CD54) may also modify susceptibility. These findings were confirmed by blocking experiments in which co-culture of target cells with ICAM-1 and LFA-3 reduced LAK and NK cytotoxicity. Study of the immunophenotypic features of each patient's neuroblastoma cells before induction of MRD may be valuable in determining the likely effect of IL2 in predicting disease reactivation.
Neuroblastoma in the child over the age of 2 is disseminated in over 70% of children at presentation (Hayes & Smith, 1989) , usually involves the bone marrow and has an extremely poor prognosis, with survival rates of under 10% reported (Look et al., 1991) . Attempts to improve the prognosis have been made by giving ablative doses of chemotherapy with autologous marrow rescue, once remission is achieved (Pritchard et al., 1982; Graham-Pole et al., 1991) . However most children still relapse and it is uncertain whether ABMT is an improvement over conventional therapy (Anderson & Coccia, 1991; .
The ability of some infants with widely disseminated disease to achieve spontaneous cure (D'Angio et al., 1991; Evans et al., 1981) would suggest that immune mechanisms may be active in this disease and that stimulation of such mechanisms might be predicted to increase the probability of disease eradication. Since neuroblastoma cells have reduced or absent class I and II antigens (Gross et al., 1990; Favrot et al., 1990; Favrot et al., 1991) , any attempt to stimulate antitumoral defense should recruit MHC unrestricted immunity (Main et al., 1985) . Both IL-2 and infusions of LAK cells have been used in neuroblastoma and tolerated (Nsar et al., 1989; Negrier et al., 1991) . Not surprisingly, in end-stage neuroblastoma, with extensive disease and involvement of the bone marrow, there is little or no benefit in this therapy, in part due to the immunologic impairment of such patients (Negrier et al., 1991; Reynolds et al., 1989 (Reittie et al., 1989) . Supporting this is the response in two !out of four neuroblastoma patients treated with IL-2 after ABMT (Negrier et al., 1991). However, the vulnerability of neuroblastoma cells to NK and LAK effector mechanisms varies widely (Duan et al., 1990; Handgretinger et al., 1989) . It is unknown why this variation occurs, but neuroblastoma cells express different levels of a number of cell adhesion molecules (CAM) and their ligands (Favrot et al., 1990; Favrot et al., 1991) . If IL2/LAK cells are to be used after ABMT as adjuvant therapy, it would be valuable to predict whether or not residual neuroblastoma cells would be susceptible to NK/ LAK cell lysis. We have therefore investigated which CAM-ligand interactions best determine neuroblastoma cell susceptibility to NK/LAK lysis.
Materials and methods
Neuroblastoma cell lines Eleven cell lines were derived in our institution from the involved bone marrows of children with neuroblastoma. Nine out of eleven of these lines were derived from tumours with amplified n-myc and amplification was maintained in in vitro culture (Brodeur et al., 1988) . Amplification of n-myc is a poor prognostic feature in neuroblastoma. Seven of these 11 lines had a normal tumour cell DNA content (D.I. of 1); again a poor prognostic feature (Look et al., 1991) .
Immunophenotyping
Immunophenotyping was performed using the methods previously described (Campana et al., 1990 were incubated with either VLA-4,ICAM-1 (CD54), LFA-1 (CDlla), or LFA-3 (CD58) antibody for 30min, immediately following incubation with 51Cr. Three concentrations, 0, 2.5 and 10 Igml-', of antibody were used for VLA-4, ICAM-1 and LFA-1, while for LFA-3, the cells were incubated either in medium alone or in the hybridoma supernatant. AD control mouse IgG was added at the same concentration. After incubation, the cells were washed twice. These antibody treated cells were then used as targets for NK and LAK cells as previously.
Results
NK and LAK cell susceptibility of the neuroblastoma cell lines varied considerably (Figure 1) . In all, however, LAK mediated lysis measured in the Cr-release assays was considerably greater than NK killing. All but one neuroblastoma line were strongly positive for GD2 and NCAM, while all were negative for LFA-1 and LFA-2. Expression of LFA-3, ICAM-1, VLA-2, VLA-4 and VLA-6, however, was more variable (shown graphically in Figure 2 ).
To determine if NK or LAK susceptibility was correlated with expression of any cellular adhesion molecule (CAM) or ligand, percentage killing vs CAM/ligand expression was plotted for each line. No correlation can exist between susceptibility to killing and the expression of cell adhesion molecules LFA-1, LFA-2, GD2 or the ligand NCAM, but although levels of VLA 2, 4 and 6 expression varied between cell lines, no correlation was seen between expression of these structures and NK or LAK killing. However, statistically significant correlations were seen between the expression of LFA-3 (the ligand for CD2) and NK and LAK killing (Figures 3a, b) . A backward stepwise model was used to assess the ability for each of LFA-3, ICAM-1, VLA-2, VLA-4 and VLA-6 to predict LAK. A backward stepwise model first includes all predictor variables in the model, and in a stepwise fashion deletes one variable at a time until only statistically significant predictor variables remain. The result in the analyses using LAK as the dependent variable was that LFA-3 was the only significant (P= 0.018) predictor variable. Now, the supporting evidence for the significance of LFA-3 as a predictor of LAK is that LFA-3 when adjusted for a model containing all other antibodies except VLA-4 remains significant (P<0.05).
Although LFA-3 is a significant predictor variable for NK killing (P = 0.026) when considered alone, its predictive ability in the presence of other antibodies is diminished. A backward stepwise analysis, similar to that for LAK described above, results in a model containing both ICAM-1 (P = 0.08) and VLA-4 (P = 0.03). The overall model is significant (P = 0.04, r2 = 0.55). These results may depend on the extreme variability (high standard deviation) of the data. Note that there is a significant correlation between LFA-3 and ICAM-l (Spearman's r = 0.60, P = 0.05).
As noted, the standard deviation exhibited by each of the antibodies is high. This led to a variance stabilising -analysis in which the natural logarithm of both the dependent and independent variables were taken and another regression analysis performed. The result of the backward stepwise regression for LN(LAK) indicates that LFA-3 is significant (P = 0.04) even in the presence of (when adjusted for) the four other antibodies. The final model includes only LN(LFA-3) (P<0.01, r2 = 0.65). Performing a similar analysis for LN(NK), LN(LFA-3) is significant when adjusted for all other antibodies except LN(ICAM-1). Again, this is probably due to power. The final model contains only LN(LFA-3) (P<0.01, r2 = 0.66).
To further establish the relevance of CAM expression to cytotoxic vulnerability, neuroblastoma cell lines were incubated with blocking antibodies prior to co-culture with effector cells. No blocking of NK and LAK killing was seen with LFA-1 or VLA-4, but after incubation with ICAM-1, eight out of eleven neuroblastoma lines showed a mean reduction of 30% (range 17-52%) (t-test, P<0.005) in LAK killing, at an effector:target ratio of 25:1 (Figure 4 ). Five out of these eight lines also showed reduction in NK killing with ICAM-1. Blocking was maximal with 2.5 fg ml-' and not further blocking was seen with 10 g ml-'. Similarly, LFA-3 reduced LAK killing in seven out of nine lines tested, by a mean of 41% (range 30-76%) (t-test, P<0.005) (Figure 5 ). LFA-3 also reduced NK killing in five of these seven lines. There was no significant blocking with either LFA-1 or VLA-4. 
I Discussion
We have shown that the variable sensitivity of neuroblastoma cells to MHC unrestricted killing appears to correlate with variation in their expression of cell adhesion molecules. Cell adhesion molecules are members of the immunoglobulin and integrin supergene families, whose extra-cellular domains participate both in the process of cell adhesion to extra-cellular proteins, and in cell-to-cell adhesion and interaction (Simmons et al., 1988; Kishimoto et al., 1987) . These molecules are integral to immune recognition and may play a role in host recognition of transformed cells (Dustin et al., 1987; Makgoba et al., 1989; Sanders et al., 1988) . We examined a number of cellular adhesion molecules and their ligands, including those previously described as present on neuroblastoma cells and those known to be important in MHC unrestricted killing (Favrot et al., 1990; Favrot et al., 1991; Gross et al., 1991; Timonen, 1990; Oblakowski et al., 1991) . We found marked differences in the ability of each of these molecules to predict the MHC unrestricted cytotoxic susceptibility of neuroblastoma cells. We confirmed that GD2 and NCAM are commonly and strongly expressed by neuroblastoma cells, so that variation in their expression would not account for differences in cytotoxic susceptibility. The VLA antigens were of greater potential interest. Not only does their expression vary between tumour cell lines, but VLA-4 has been reported to be required for cell-mediated lysis of melanoma, another tumour derived from neural crest cells (Anichini et al., 1990) . However, no correlation was found between expression of VLA-4 and susceptibility to NK/LAK lysis and antibody to VLA-4 had no effect on the susceptibility of neuroblastoma lines to cytotoxic effector cells. The VLA receptor ligand system is not therefore of generic importance in interactions of neural crest-derived tumour cells with effector cells of the immune system.
Of all the receptor-ligand systems studied, only LFA-3 (the ligand for LFA-2) and ICAM-1 (the ligand for LFA-1) could be shown to be important in determining susceptibility to MHC unrestricted lysis. Thus, the percentage expression of LFA-3 correlated with cytotoxic susceptibility and the two lines that were least susceptible to killing were both <1% ICAM-l positive. The data also imply that only low levels of ICAM-l expression are required to achieve the maximum susceptibility conferred by this ligand, since it was only at the lowest levels of expression that this molecule appeared to influence the vulnerability of the target cell line.
The importance of LFA-3 and ICAM-1 expression in determining the susceptibility to lysis was confirmed by blocking studies. The majority of the lines tested showing substantial blocking with each antibody. The ability of anti-ICAM-1 monoclonal antibody to block lysis also excludes the possibility that ICAM-1 iteself predicted susceptibility to NK/LAK lysis only because it is co-expressed with LFA-3.
Whether or not this study is relevant to assessing the NK/LAK sensitivity of fresh tumour cells depends on whether ligand expression in vivo is similar to that of the neuroblastoma cell lines studied. ICAM-1 expression in clinical specimens at diagnosis has been shown to be restricted to a minority of neuroblastomas. Intriguingly, however, this subset of tumours has a favourable outlook, further supporting the concept that expression of ligands for cell adhesion molecules may determine susceptibility to immune system clearance mechanisms, and improve prognosis. Similarly, LFA-3 was expressed in vivo in only a minority of low stage, well differentiated, good prognosis tumours (Favrot et al., 1991) . LFA-3 expression can also be induced in vivo -even in some high stage undifferentiated tumours -by chemotherapy (Favrot et al., 1991) . If LFA-3 and ICAM-1 do indeed confer susceptibility to NK/LAK killing then assessment of tumour susceptibility might most appropriately be made after exposure to chemotherapy and a decision then made as to whether it was appropriate to progress to ABMT and/or therapy with immunostimulators such as IL2. Finally, it will be of interest to discover whether expression of cell adhesion molecules modifies MHC restricted, antigen specific, T cell killing of neuroblastoma cells, if such killing exists (Brenner et al., 1992) .
